RT Journal Article
SR Electronic
T1 Pushing beyond specifications: Evaluation of linearity and clinical performance of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.28.20115469
DO 10.1101/2020.05.28.20115469
A1 Nörz, Dominik
A1 Frontzek, André
A1 Eigner, Ulrich
A1 Oestereich, Lisa
A1 Fischer, Nicole
A1 Aepfelbacher, Martin
A1 Pfefferle, Susanne
A1 Lütgehetmann, Marc
YR 2020
UL http://medrxiv.org/content/early/2020/05/30/2020.05.28.20115469.abstract
AB Background The ongoing SARS-CoV-2 pandemic presents a unique challenge to diagnostic laboratories. There are preliminary studies correlating qRT-PCR results from different materials to clinical outcomes, yet, comparability is limited due to the plethora of different assays used for diagnostics. In this study we evaluate clinical performance and linear range for the SARS-CoV-2 IVD (cobas6800/8800 system, a fully automated sample-to-result platform) in different clinically relevant matrix materials outside official specifications.Methods Assay performance was assessed in human plasma, BAL/BL and transport medium following chemical inactivation. For analytical evaluation, respective matrix materials were spiked with SARS-CoV-2 RNA in ten-fold dilution series. The efficacy of chemical inactivation by guanidine hydrochloride solution was confirmed in cell culture infectivity experiments. For correlation, a total of 235 predetermined clinical samples including respiratory swabs, plasma and BAL/BL were subjected to the SARS-CoV-2 IVD test and results were compared.Results The SARS-CoV-2 IVD showed excellent linearity over five to seven log steps depending on matrix material. Chemical inactivation resulted in a reduction in plaque forming units of at least 3.5 log steps, while having no significant impact on assay performance. Inter-run consistency from three different testing sites demonstrated excellent comparability of RT-PCR results (maximum deviation was 1.53 CT). Clinical evaluation for respiratory swabs showed very good agreement with the comparator assay (Positive agreement 95.7%, negative agreement 98.9%).Conclusion The SARS-CoV-2 IVD test for the cobas6800/8800 systems offers excellent linear range and inter-run consistency for quantification of SARS-CoV-2 RNA in different matrices outside official specifications.HighlightsEffective reduction of SARS-CoV-2 infectivity by chemical inactivation without affecting assay performance.SARS-CoV-2 IVD for the cobas 6800/8800 is linear over up to seven log steps in different materials including human plasma.Minimal variance of CT values between testing sites indicates high comparability of quantification results.Competing Interest StatementUE and ML received speaker honaria and related travel expenses from Roche Diagnostics. Parts of the material used for this study were provided by Roche Molecular Solutions (Pleasanton, USA).Funding StatementParts of the material used for this study were provided by Roche Molecular Solutions (Pleasanton, USA). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was conducted in accordance with paragraph 12 of the Hamburg hospital law (paragraph 12 HmbKHG). The use of anonymized samples was approved by the ethics committee, Freie und Hansestadt Hamburg, PV5626.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable on request.